An observational study in Gastric MALT Lymphoma, sponsored by Seoul National University Hospital. Recruiting at 3 sites in South Korea. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Seoul National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of — 6 open to participants now, 10 under way, 3 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Korea, Republic of.
Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 31st registered.
875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →6 of the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Australia and 9 more countries
Ages 18+
International Extranodal Lymphoma Study Group (IELSG) · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Korea, Republic of, United States, Australia and 15 more countries
Ages 18+
BeOne Medicines · Sites in Korea, Republic of, United States, Australia and 13 more countries
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 8
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 168 across 65 observational studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 97 across the 29 interventional studies, 300 across the 4 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 33 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,902 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 4 studies filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
4 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700149International Extranodal Lymphoma Study Group (IELSG)Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | 2026-12-31 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
| NCT07173790Seoul National University HospitalWatch and Wait or Worry and Wait in Indolent Lymphoma | 2027-09-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls.
Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).
Eligible patients who visited participating hospital will be asked, and upon providing informed consent, will be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
[MALT lymphoma group]
Patients who underwent
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who were newly diagnosed as gastric MALT lymphoma
Other: MALT lymphoma
Patients who underwent 1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis, 2. therapeutic upper endoscopy for gastric hyperplastic polyps, or 3. screening upper endoscopy without any symptoms.
New diagnosis with gastric MALT lymphoma
Remission of gastric MALT lymphoma
Remission of gastric MALT lymphoma
Time frame: Within 3 years from diagnosis
Eradication of H. pylori infection
Eradication of H. pylori infection
Time frame: Within 6 month from eradication therapy
Plan to share: No — IPD will not be shared due to data protection policy of the participating institutions.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2028, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, B-Cell, Marginal Zone →
Seoul National University Hospital →